Statement of Changes in Beneficial Ownership (4)
October 18 2019 - 5:14PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Truitt Joseph |
2. Issuer Name and Ticker or Trading Symbol
ACHILLION PHARMACEUTICALS INC
[
ACHN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer
|
(Last)
(First)
(Middle)
C/O ACHILLION PHARMACEUTICALS, INC., 1777 SENTRY PARKWAY W, BLDG 14, STE 200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/16/2019
|
(Street)
BLUE BELL, PA 19422
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
10/16/2019
|
|
M
|
|
100234.00
|
A
|
$3.10
|
103734.00
|
D
|
|
Common Stock
|
10/16/2019
|
|
M
|
|
33250.00
|
A
|
$3.28
|
136984.00
|
D
|
|
Common Stock
|
10/16/2019
|
|
S
|
|
100234.00
|
D
|
$6.3749
|
36750.00
|
D
|
|
Common Stock
|
10/16/2019
|
|
S
|
|
33250.00
|
D
|
$6.3749
|
3500.00
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right to Buy)
|
$3.28
|
10/16/2019
|
|
M
|
|
|
33250.00
|
(1)
|
12/18/2019
|
Common Stock
|
33250.00
|
$0.00
|
0.00
|
D
|
|
Stock Option (Right to Buy)
|
$3.10
|
10/16/2019
|
|
M
|
|
|
100234.00
|
(2)
|
12/16/2020
|
Common Stock
|
100234.00
|
$0.00
|
87766.00
|
D
|
|
Explanation of Responses:
|
(1)
|
This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
|
(2)
|
This option was granted on December 16, 2010 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
|
Remarks: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Truitt on March 8, 2018. |
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Truitt Joseph C/O ACHILLION PHARMACEUTICALS, INC. 1777 SENTRY PARKWAY W, BLDG 14, STE 200 BLUE BELL, PA 19422
|
X
|
|
Chief Executive Officer
|
|
Signatures
|
/s/ Joseph Truitt
|
|
10/18/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Jul 2023 to Jul 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.